NERV Minerva Neurosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1598646 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,973.5%
TTM EPS YoY-1,728.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-460.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets187.3%
Debt / equity—
Current ratio33.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-410.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $0 | $0 | $0 |
| R&D expense | $5.76M | $11.90M | $12.71M | $14.65M | $32.04M |
| SG&A expense | $9.34M | $9.95M | $10.41M | $10.58M | $13.33M |
| Operating income | -$15.10M | -$21.85M | -$23.12M | -$25.23M | -$45.37M |
| Pretax income | — | — | — | -$32.11M | -$51.71M |
| Income tax | — | — | — | — | -$1.80M |
| Net income | -$293.42M | $1.44M | -$30.01M | -$32.11M | -$49.91M |
| EBITDA | -$15.10M | -$21.84M | -$23.11M | — | — |
| EPS (basic) | -34.67 | 0.19 | -4.61 | -6.01 | -9.35 |
| EPS (diluted) | -34.67 | 0.19 | -4.61 | -6.01 | -9.35 |
| Weighted avg. shares (diluted) | 8.46M | 7.57M | 6.51M | 5.34M | 5.34M |
| Balance sheet | |||||
| Cash & equivalents | $82.30M | $21.36M | $40.91M | $36.09M | $60.76M |
| Current assets | $83.10M | $22.27M | $42.00M | $40.16M | $62.20M |
| PP&E, net | $0 | $5,442 | $10,884 | $16,326 | — |
| Goodwill | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M |
| Total assets | $97.97M | $37.14M | $56.90M | $55.09M | $77.12M |
| Current liabilities | $2.29M | $2.84M | $3.34M | $1.38M | $2.82M |
| Total liabilities | $233.76M | $62.84M | $85.36M | $75.11M | $69.15M |
| Shareholders' equity | -$140.75M | -$25.69M | -$28.46M | -$20.02M | $7.98M |
| Shares outstanding | 43.27M | 6.99M | 6.99M | 5.34M | 5.34M |
| Cash flow statement | |||||
| Operating cash flow | -$13.51M | -$19.55M | -$14.78M | -$24.65M | -$24.60M |
| Capital expenditure | — | — | — | $16,326 | — |
| Free cash flow | — | — | — | -$24.66M | — |
| Investing cash flow | $0 | $0 | $0 | -$16,326 | — |
| Financing cash flow | $74.45M | — | $19.60M | -$5 | $60.00M |
| Depreciation & amortization | $5,442 | $5,442 | $5,442 | — | — |
| Stock-based compensation | $1.33M | $1.33M | $1.97M | $4.11M | $5.22M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.